Evaluation of the immune response of a H7N9 candidate vaccine virus derived from the fifth wave A/Guangdong/17SF003/2016

Highly pathogenic influenza H7N9 viruses that emerged in the fifth wave of H7N9 outbreak pose a risk to human health. The World Health Organization has updated the candidate vaccine viruses for H7N9 viruses recently. In this study, we evaluated the immune response to an updated H7N9 candidate vaccin...

Full description

Saved in:
Bibliographic Details
Published inAntiviral research Vol. 177; p. 104776
Main Authors Dong, Ji, Chen, Peihai, Wang, Yang, Lv, Yunhua, Xiao, Ji, Li, Qinming, Li, Zhixia, Zhang, Beiwu, Niu, Xuefeng, Li, Chufang, Pan, Weiqi, Chen, Ling
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.05.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Highly pathogenic influenza H7N9 viruses that emerged in the fifth wave of H7N9 outbreak pose a risk to human health. The World Health Organization has updated the candidate vaccine viruses for H7N9 viruses recently. In this study, we evaluated the immune response to an updated H7N9 candidate vaccine virus, which derived from the highly pathogenic A/Guangdong/17SF003/2016 (GD/16) in mice and rhesus macaques. GD/16 vaccination elicited robust neutralizing, virus-specific immunoglobulin G antibodies and effective protection, but poor hemagglutination inhibition antibody titers. Furthermore, mouse and rhesus macaque serum raised against the previous H7N9 CVV A/Anhui/1/2013 (AH/13) were tested for its cross-reactivity to GD/16 virus. We found that although AH/13-immune serum has poor hemagglutination inhibition reactivity against GD/16 virus, AH/13 elicit efficient cross-neutralizing antibodies and in vivo protection against GD/16. Further studies showed that the hemagglutinin of GD/16 has strong receptor binding avidity, which might be associated with the decreased hemagglutination inhibition assay sensitivity. This study underscores the point that receptor binding avidity should be taken into account when performing quantitative interpretation of hemagglutination inhibition data. A combination of multiple serological assays is required for accurate vaccine evaluation and antigenic analysis of influenza viruses. •Systemically evaluated the immune response to H7N9 CVV A/Guangdong/17SF003/2016 (GD/16) in mice and rhesus macaques.•GD/16 elicited robust neutralizing and IgG antibodies, but poor hemagglutination inhibition antibody titers.•Receptor binding avidity should be considered in interpretation of HI data for evaluation of influenza antigenic variation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2020.104776